Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer

Gynecologic Oncology

Volumn 131, Issue 2, 2013, Pages 315-320

  Goodwin, Rachel A ^a   Jamal, Rahima ^b   Tu, Dongsheng ^c   Walsh, Wendy ^c   Dancey, Janet ^c   Oza, Amit M ^d   Elit, Laurie ^e   Eisenhauer, Elizabeth A ^c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Endometrial cancer; mTOR inhibitors; Predictors of response; Temsirolimus

Indexed keywords

CHOLESTEROL; GLUCOSE; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMSIROLIMUS; TRIACYLGLYCEROL;

ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHOLESTEROL BLOOD LEVEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM ADENOSQUAMOUS CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; METASTATIC ENDOMETRIAL CANCER; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR GROWTH; TUMOR VOLUME;

ENDOMETRIAL CANCER; MTOR INHIBITORS; PREDICTORS OF RESPONSE; TEMSIROLIMUS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOSQUAMOUS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SIROLIMUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886027192     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.08.004     Document Type: Article

References (21)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. G. Emons, and W. Heyl Hormonal treatment of endometrial cancer J Cancer Res Clin Oncol 126 2000 619 623
3. S.S. Lentz, M.F. Brady, F.J. Major, G.C. Reid, and J.T. Soper High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 14 1996 357 361
4. J.T. Thigpen, M.F. Brady, and R.D. Alvarez Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group J Clin Oncol 17 1999 1736 1744
5. K.C. Podratz, P.C. O'Brien, G.D. Malkasian Jr., D.G. Decker, J.A. Jefferies, and J.H. Edmonson Effects of progestational agents in treatment of endometrial carcinoma Obstet Gynecol 66 1985 106 110
6. J. Bonte, P. Ide, G. Billiet, and P. Wynants Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma Gynecol Oncol 11 1981 140 161
7. K.D. Swenerton, G.W. White, and D.A. Boyes Treatment of advanced endometrial carcinoma with tamoxifen N Engl J Med 301 1979 105
8. T. Thigpen, M.F. Brady, H.D. Homesley, J.T. Soper, and J. Bell Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 19 2001 364 367
9. S. Bellone, H.R. Shah, J.K. McKenney, P.J. Stone, and A.D. Santin Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole Am J Obstet Gynecol 199 2008 e7 e10
10. B.B. Ma, A. Oza, and E. Eisenhauer The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group Int J Gynecol Cancer 14 2004 650 658
11. G.F. Fleming, V.L. Brunetto, and D. Cella Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 22 2004 2159 2166
12. E. Latta, and W.B. Chapman PTEN mutations and evolving concepts in endometrial neoplasia Curr Opin Obstet Gynecol 14 2002 59 65
13. Y. Kanamori, J. Kigawa, and H. Itamochi Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma Clin Cancer Res 7 2001 892 895
14. A.M. Oza, L. Elit, and M.S. Tsao et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J Clin Oncol 29 2011 3278 3285
15. B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark, and P.J. Cagnoni Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies Clin Cancer Res 13 2007 3913 3921
16. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048
17. R. Goodwin, K. Ding, and L. Seymour et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24 Ann Oncol 21 2010 2220 2226
18. B.I. Rini, D.P. Cohen, and D.R. Lu et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773
19. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
20. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
21. R.S. De Souza PL, and J. Beck Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha J Clin Oncol 26 2008 511 [abst]